Possible role of Thiazolidinedione in the management of Type-II Endometrial Cancer
Type-II Endometrial Cancer (EMC) is one of the most common types of gynaecological cancer affecting more than 2.7 million people worldwide. Clinical evidence shows that adipokines levels are abnormally altered in Type-II EMC and reported to be one of the major responsible factor for uncontrolled pro...
Gespeichert in:
| Veröffentlicht in: | Medical hypotheses 2019-05, Vol.126, p.78-81 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 81 |
|---|---|
| container_issue | |
| container_start_page | 78 |
| container_title | Medical hypotheses |
| container_volume | 126 |
| creator | Garikapati, Kusuma Kumari Ammu, V.V.V. Ravi Kiran Krishnamurthy, Praveen T. Chintamaneni, Pavan Kumar Pindiprolu, Sai kiran S.S. |
| description | Type-II Endometrial Cancer (EMC) is one of the most common types of gynaecological cancer affecting more than 2.7 million people worldwide. Clinical evidence shows that adipokines levels are abnormally altered in Type-II EMC and reported to be one of the major responsible factor for uncontrolled proliferation and metastasis in Type-II EMC. Reversing the altered adipokine levels, therefore, help to control Type-II EMC proliferation and metastasis. In the present hypothesis we focus on the possible role of Thiazolidinediones in favourably altering the adipokine levels to benefit in the management of Type-II EMC. |
| doi_str_mv | 10.1016/j.mehy.2019.03.014 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2213151919</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0306987718313513</els_id><sourcerecordid>2213151919</sourcerecordid><originalsourceid>FETCH-LOGICAL-c356t-4d6e3940055fde02df7c472bfaab8f3d30d3f886638d45ebb5b22103b35e2eca3</originalsourceid><addsrcrecordid>eNp9kD1PwzAURS0EoqXwBxhQRpaEZzvOh8SCqgKVkECozJYTv1BXSVzsFKn8elxaGFneW8690j2EXFJIKNDsZpV0uNwmDGiZAE-ApkdkTAVnMcvz_JiMgUMWl0Wej8iZ9ysAKFNenJIRD3kQkI7J64v13lQtRs6GY5tosTTqy7ZGmx61sT1Gpo-GJUad6tU7dtgPP9h2jfF8Hs16bTscnFFtNFV9je6cnDSq9Xhx-BPydj9bTB_jp-eH-fTuKa65yIY41RnyMgUQotEITDd5neasapSqioZrDpo3RZFlvNCpwKoSFWMUeMUFMqwVn5Drfe_a2Y8N-kF2xtfYtqpHu_Ey0JwKWtIyoGyP1i7MddjItTOdcltJQe5cypXcuZQ7lxK4DC5D6OrQv6k61H-RX3kBuN0DGFZ-GnTS1waDAm0c1oPU1vzX_w2DAIVb</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2213151919</pqid></control><display><type>article</type><title>Possible role of Thiazolidinedione in the management of Type-II Endometrial Cancer</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Garikapati, Kusuma Kumari ; Ammu, V.V.V. Ravi Kiran ; Krishnamurthy, Praveen T. ; Chintamaneni, Pavan Kumar ; Pindiprolu, Sai kiran S.S.</creator><creatorcontrib>Garikapati, Kusuma Kumari ; Ammu, V.V.V. Ravi Kiran ; Krishnamurthy, Praveen T. ; Chintamaneni, Pavan Kumar ; Pindiprolu, Sai kiran S.S.</creatorcontrib><description>Type-II Endometrial Cancer (EMC) is one of the most common types of gynaecological cancer affecting more than 2.7 million people worldwide. Clinical evidence shows that adipokines levels are abnormally altered in Type-II EMC and reported to be one of the major responsible factor for uncontrolled proliferation and metastasis in Type-II EMC. Reversing the altered adipokine levels, therefore, help to control Type-II EMC proliferation and metastasis. In the present hypothesis we focus on the possible role of Thiazolidinediones in favourably altering the adipokine levels to benefit in the management of Type-II EMC.</description><identifier>ISSN: 0306-9877</identifier><identifier>EISSN: 1532-2777</identifier><identifier>DOI: 10.1016/j.mehy.2019.03.014</identifier><identifier>PMID: 31010504</identifier><language>eng</language><publisher>United States: Elsevier Ltd</publisher><subject>Adipokines ; Adipokines - metabolism ; Adiponectin ; Adiponectin - metabolism ; Animals ; Cell Proliferation ; Endometrial Neoplasms - drug therapy ; Endometrial Neoplasms - metabolism ; Female ; Gene Expression Regulation ; Humans ; Leptin ; Leptin - metabolism ; Mice ; Models, Biological ; Neoplasm Metastasis ; Resistin ; Resistin - metabolism ; Thiazolidinediones ; Thiazolidinediones - therapeutic use ; Type-II Endometrial Cancer ; Visfatin</subject><ispartof>Medical hypotheses, 2019-05, Vol.126, p.78-81</ispartof><rights>2019 Elsevier Ltd</rights><rights>Copyright © 2019 Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c356t-4d6e3940055fde02df7c472bfaab8f3d30d3f886638d45ebb5b22103b35e2eca3</citedby><cites>FETCH-LOGICAL-c356t-4d6e3940055fde02df7c472bfaab8f3d30d3f886638d45ebb5b22103b35e2eca3</cites><orcidid>0000-0002-8655-7680</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.mehy.2019.03.014$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31010504$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Garikapati, Kusuma Kumari</creatorcontrib><creatorcontrib>Ammu, V.V.V. Ravi Kiran</creatorcontrib><creatorcontrib>Krishnamurthy, Praveen T.</creatorcontrib><creatorcontrib>Chintamaneni, Pavan Kumar</creatorcontrib><creatorcontrib>Pindiprolu, Sai kiran S.S.</creatorcontrib><title>Possible role of Thiazolidinedione in the management of Type-II Endometrial Cancer</title><title>Medical hypotheses</title><addtitle>Med Hypotheses</addtitle><description>Type-II Endometrial Cancer (EMC) is one of the most common types of gynaecological cancer affecting more than 2.7 million people worldwide. Clinical evidence shows that adipokines levels are abnormally altered in Type-II EMC and reported to be one of the major responsible factor for uncontrolled proliferation and metastasis in Type-II EMC. Reversing the altered adipokine levels, therefore, help to control Type-II EMC proliferation and metastasis. In the present hypothesis we focus on the possible role of Thiazolidinediones in favourably altering the adipokine levels to benefit in the management of Type-II EMC.</description><subject>Adipokines</subject><subject>Adipokines - metabolism</subject><subject>Adiponectin</subject><subject>Adiponectin - metabolism</subject><subject>Animals</subject><subject>Cell Proliferation</subject><subject>Endometrial Neoplasms - drug therapy</subject><subject>Endometrial Neoplasms - metabolism</subject><subject>Female</subject><subject>Gene Expression Regulation</subject><subject>Humans</subject><subject>Leptin</subject><subject>Leptin - metabolism</subject><subject>Mice</subject><subject>Models, Biological</subject><subject>Neoplasm Metastasis</subject><subject>Resistin</subject><subject>Resistin - metabolism</subject><subject>Thiazolidinediones</subject><subject>Thiazolidinediones - therapeutic use</subject><subject>Type-II Endometrial Cancer</subject><subject>Visfatin</subject><issn>0306-9877</issn><issn>1532-2777</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kD1PwzAURS0EoqXwBxhQRpaEZzvOh8SCqgKVkECozJYTv1BXSVzsFKn8elxaGFneW8690j2EXFJIKNDsZpV0uNwmDGiZAE-ApkdkTAVnMcvz_JiMgUMWl0Wej8iZ9ysAKFNenJIRD3kQkI7J64v13lQtRs6GY5tosTTqy7ZGmx61sT1Gpo-GJUad6tU7dtgPP9h2jfF8Hs16bTscnFFtNFV9je6cnDSq9Xhx-BPydj9bTB_jp-eH-fTuKa65yIY41RnyMgUQotEITDd5neasapSqioZrDpo3RZFlvNCpwKoSFWMUeMUFMqwVn5Drfe_a2Y8N-kF2xtfYtqpHu_Ey0JwKWtIyoGyP1i7MddjItTOdcltJQe5cypXcuZQ7lxK4DC5D6OrQv6k61H-RX3kBuN0DGFZ-GnTS1waDAm0c1oPU1vzX_w2DAIVb</recordid><startdate>201905</startdate><enddate>201905</enddate><creator>Garikapati, Kusuma Kumari</creator><creator>Ammu, V.V.V. Ravi Kiran</creator><creator>Krishnamurthy, Praveen T.</creator><creator>Chintamaneni, Pavan Kumar</creator><creator>Pindiprolu, Sai kiran S.S.</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-8655-7680</orcidid></search><sort><creationdate>201905</creationdate><title>Possible role of Thiazolidinedione in the management of Type-II Endometrial Cancer</title><author>Garikapati, Kusuma Kumari ; Ammu, V.V.V. Ravi Kiran ; Krishnamurthy, Praveen T. ; Chintamaneni, Pavan Kumar ; Pindiprolu, Sai kiran S.S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c356t-4d6e3940055fde02df7c472bfaab8f3d30d3f886638d45ebb5b22103b35e2eca3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Adipokines</topic><topic>Adipokines - metabolism</topic><topic>Adiponectin</topic><topic>Adiponectin - metabolism</topic><topic>Animals</topic><topic>Cell Proliferation</topic><topic>Endometrial Neoplasms - drug therapy</topic><topic>Endometrial Neoplasms - metabolism</topic><topic>Female</topic><topic>Gene Expression Regulation</topic><topic>Humans</topic><topic>Leptin</topic><topic>Leptin - metabolism</topic><topic>Mice</topic><topic>Models, Biological</topic><topic>Neoplasm Metastasis</topic><topic>Resistin</topic><topic>Resistin - metabolism</topic><topic>Thiazolidinediones</topic><topic>Thiazolidinediones - therapeutic use</topic><topic>Type-II Endometrial Cancer</topic><topic>Visfatin</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Garikapati, Kusuma Kumari</creatorcontrib><creatorcontrib>Ammu, V.V.V. Ravi Kiran</creatorcontrib><creatorcontrib>Krishnamurthy, Praveen T.</creatorcontrib><creatorcontrib>Chintamaneni, Pavan Kumar</creatorcontrib><creatorcontrib>Pindiprolu, Sai kiran S.S.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Medical hypotheses</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Garikapati, Kusuma Kumari</au><au>Ammu, V.V.V. Ravi Kiran</au><au>Krishnamurthy, Praveen T.</au><au>Chintamaneni, Pavan Kumar</au><au>Pindiprolu, Sai kiran S.S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Possible role of Thiazolidinedione in the management of Type-II Endometrial Cancer</atitle><jtitle>Medical hypotheses</jtitle><addtitle>Med Hypotheses</addtitle><date>2019-05</date><risdate>2019</risdate><volume>126</volume><spage>78</spage><epage>81</epage><pages>78-81</pages><issn>0306-9877</issn><eissn>1532-2777</eissn><abstract>Type-II Endometrial Cancer (EMC) is one of the most common types of gynaecological cancer affecting more than 2.7 million people worldwide. Clinical evidence shows that adipokines levels are abnormally altered in Type-II EMC and reported to be one of the major responsible factor for uncontrolled proliferation and metastasis in Type-II EMC. Reversing the altered adipokine levels, therefore, help to control Type-II EMC proliferation and metastasis. In the present hypothesis we focus on the possible role of Thiazolidinediones in favourably altering the adipokine levels to benefit in the management of Type-II EMC.</abstract><cop>United States</cop><pub>Elsevier Ltd</pub><pmid>31010504</pmid><doi>10.1016/j.mehy.2019.03.014</doi><tpages>4</tpages><orcidid>https://orcid.org/0000-0002-8655-7680</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0306-9877 |
| ispartof | Medical hypotheses, 2019-05, Vol.126, p.78-81 |
| issn | 0306-9877 1532-2777 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2213151919 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Adipokines Adipokines - metabolism Adiponectin Adiponectin - metabolism Animals Cell Proliferation Endometrial Neoplasms - drug therapy Endometrial Neoplasms - metabolism Female Gene Expression Regulation Humans Leptin Leptin - metabolism Mice Models, Biological Neoplasm Metastasis Resistin Resistin - metabolism Thiazolidinediones Thiazolidinediones - therapeutic use Type-II Endometrial Cancer Visfatin |
| title | Possible role of Thiazolidinedione in the management of Type-II Endometrial Cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-20T06%3A03%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Possible%20role%20of%20Thiazolidinedione%20in%20the%20management%20of%20Type-II%20Endometrial%20Cancer&rft.jtitle=Medical%20hypotheses&rft.au=Garikapati,%20Kusuma%20Kumari&rft.date=2019-05&rft.volume=126&rft.spage=78&rft.epage=81&rft.pages=78-81&rft.issn=0306-9877&rft.eissn=1532-2777&rft_id=info:doi/10.1016/j.mehy.2019.03.014&rft_dat=%3Cproquest_cross%3E2213151919%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2213151919&rft_id=info:pmid/31010504&rft_els_id=S0306987718313513&rfr_iscdi=true |